Newbury Pharmaceuticals
1.08 SEK
+1.41 %
Less than 1K followers
NEWBRY
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Newbury Pharmaceuticals
P/B
Median 2022-2025
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Share price (SEK) | 4.44 | 4.00 | 3.30 | 2.59 |
| Shares | 19.5 | 19.5 | 19.5 | 30.4 |
| Market cap | 86.7 | 78.1 | 64.4 | 78.7 |
| Enterprise value | - | - | - | - |
| EV/S | - | - | - | - |
| EV/EBITDA | - | - | - | - |
| EV/EBIT | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. |
| P/B | 1.26 | 1.58 | 1.24 | 1.84 |
| P/S | 15.7 | 7.6 | 1.7 | 2.5 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 79.1 % | 67.7 % | 57.1 % | 55.3 % |
| Gearing ratio | - | - | - | - |